JP2001507696A - グルタチオンの医薬製剤およびその投与方法 - Google Patents
グルタチオンの医薬製剤およびその投与方法Info
- Publication number
- JP2001507696A JP2001507696A JP53020698A JP53020698A JP2001507696A JP 2001507696 A JP2001507696 A JP 2001507696A JP 53020698 A JP53020698 A JP 53020698A JP 53020698 A JP53020698 A JP 53020698A JP 2001507696 A JP2001507696 A JP 2001507696A
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- mammal
- gsh
- cells
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.迅速に溶解する処方中のカプセル化された医薬的に安定化されたグルタチ オンの経口ボーラスを胃が空の哺乳動物に投与することを特徴とする哺乳動物細 胞においてグルタチオンレベルを増加させる方法。 2.該哺乳動物がRNAウイルスで感染される請求項1記載の方法。 3.該ウイルスがレトロウイルスである請求項2記載の方法。 4.該レトロウイルスがHIVである請求項3記載の方法。 5.該哺乳動物が500より大きいCD4+細胞計数を有するヒトである請求 項4記載の方法。 6.該哺乳動物がAIDSを有するヒトである請求項4記載の方法。 7.該ウイルスが狂犬病ウイルスである請求項2記載の方法。 8.該哺乳動物をヘルペスウイルスで感染させる請求項1記載の方法。 9.該ヘルペスウイルスがヒト・ヘルペスウイルスである請求項8記載の方法 。 10.該哺乳動物が糖尿病を有する請求項1記載の方法。 11.該哺乳動物が生理学的に上昇した血中グルコースのレベルを有する請求 項1記載の方法。 12.還元グルタチオンを生成する哺乳動物細胞中の酵素がグリケート化され ている請求項11記載の方法。 13.該哺乳動物が鬱血性心不全を有する請求項1記載の方法。 14.該哺乳動物が一酸化窒素の貧弱な利用に起因する血管収縮および得られ た増大した末梢血管耐性を有する請求項1記載の方法。 15.該哺乳動物が制御されないフリーラジカル酸化を促進する毒性化合物に 暴露される請求項1記載の方法。 16.該化合物がアルコールである請求項15記載の方法。 17.該アルコールがエタノールである請求項16記載の方法。 18.該化合物がアセトアミノフェンである請求項15記載の方法。 19.該哺乳動物が肝炎を有する請求項1記載の方法。 20.該肝炎が感染性肝炎である請求項19記載の方法。 21.迅速に溶解する処方中のカプセル化された医薬的に安定化されたグルタ チオンがハードゼラチンカプセル中の約250mgの結晶性アスコルビン酸を含 む請求項1記載の方法。 22.該グルタチオンがアスコルビン酸で医薬的に安定化された請求項1記載 の方法。 23.該アスコルビン酸がグルタチオンに対して重量で約1:1ないし1:1 0の量で存在する請求項22記載の方法。 24.該グルタチオンを静菌剤でカプセル化する請求項1記載の方法。 25.該静菌剤が結晶性アスコルビン酸である請求項24記載の方法。 26.該哺乳動物がアルツハイマー病を有するヒトである請求項1記載の方法 。 27.該哺乳動物がパーキンソン病を有する請求項1記載の方法。 28.該哺乳動物がカテコールアミン−関連毒性を有する請求項1記載の方法 。 29.該哺乳動物が悪性メラノーマを有するヒトである請求項1記載の方法。 30.該哺乳動物がアテローム性動脈硬化症である請求項1記載の方法。 31.該哺乳動物が黄斑変性を有する請求項1記載の方法。 32.該哺乳動物が白内障を有する請求項1記載の方法。 33.該哺乳動物が緑内障を有する請求項1記載の方法。 34.該哺乳動物が成人呼吸促進症候群(ARDS)である請求項1記載の方 法。 35.該哺乳動物が気腫を有する請求項1記載の方法。 36.該哺乳動物が肺の線維嚢胞病を有する請求項1記載の方法。 37.該哺乳動物が石綿症を有する請求項1記載の方法。 38.該哺乳動物がアルツハイマー病を有するヒトである請求項1記載の方法 。 39.該グルタチオンが哺乳動物細胞の悪性形質転換を妨げる請求項1記載の 方法。 40.該哺乳動物が金属イオン毒性を有する請求項1記載の方法。 41.該金属イオンがカドミウム、鉛、水銀、銅、鉄、セレン、テルル、アク チノイドおよび超ウラン元素よりなる群から選択される請求項1記載の方法。 42.該哺乳動物が該投与と組み合わせてイオン化放射に付される請求項1記 載の方法。 43.該放射がバックグラウンドレベルを超えるレベルである請求項42記載 の方法。 44.該哺乳動物が毒性雰囲気ガスに付される請求項1記載の方法。 45.該毒性ガスがオゾン、窒素の酸化物、および硫黄の酸化物よりなる群か ら選択される請求項44記載の方法。 46.該哺乳動物が腸の炎症病を有する請求項1記載の方法。 47.該炎症病が限局性腸炎および潰瘍性結腸炎よりなる群から選択される請 求項4記載の方法。 48.該哺乳動物に癌化学療法剤を投与する請求項1記載の方法。 49.該癌化学療法剤がシスプラチン、ドキソルビシン、およびダウノルビシ ンよりなる群から選択される請求項48記載の方法。 50.該哺乳動物が急性負傷に罹った請求項1記載の方法。 51.該負傷が脊髄負傷、脳負傷、眼、および末梢神経障害よりなる群から選 択される請求項50記載の方法。 52.該哺乳動物がハロゲン化炭化水素毒性に罹った請求項1記載の方法。 53.還元グルタチオンを十分量の流体に添加してウイルス蛋白質を減少させ ることを特徴とする体外ヒト体液中のウイルスを不活化する方法。 54.該ヒト体液が血液製品を含む請求項53記載の方法。 55.十二指腸中のグルタチオン1グラム当たり約10グラム未満の 食品と共に、安定化グルタチオンを経口投与して、少なくとも約500マイクロ モルの十二指腸中の効果的な濃度を達成することを特徴とする哺乳動物細胞にお いてグルタチオンレベルを増加させる方法。 56.十二指腸中でグルタチオンの少なくとも一部を放出するのに適合した医 薬投与形態中にて、実質的に還元されたL−グルタチオンおよび還元剤組成物を 還元された条件に維持し、引き続いて、胃が実質的に空の時に該医薬投与形態を 投与し、それにより、十二指腸に放出されたグルタチオンの一部の吸収が約40 %を超えることを特徴とする哺乳動物にグルタチオンを投与する方法。 57.還元剤組成物と混合した実質的に還元されたL−グルタチオンの医薬処 方を還元された条件に維持し、十二指腸をライニングする細胞中のグルタチオン の濃度を超える十二指腸中のグルタチオン濃度を達成し、胃、十二指腸および回 腸の上方の1/3中で投与されたグルタチオンの約10%未満をオプサルミック 酸に変換するのを促進するように、胃医薬処方を投与することを特徴とするヒト の組織におけるグルタチオンレベルを増大させる方法。 58.経粘膜投与用の、その中にグルタチオンまたはその誘導体を有する乾燥 ゲルマトリックスを含む医薬処方。 59.該グルタチオンがニトロソーグルタチオンとして誘導体化された請求項 58記載の医薬処方。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3410196P | 1996-12-31 | 1996-12-31 | |
US60/034,101 | 1996-12-31 | ||
PCT/US1997/023879 WO1998029101A1 (en) | 1996-12-31 | 1997-12-31 | Pharmaceutical preparations of glutathione and methods of administration thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001507696A true JP2001507696A (ja) | 2001-06-12 |
JP2001507696A5 JP2001507696A5 (ja) | 2006-01-05 |
Family
ID=21874315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53020698A Pending JP2001507696A (ja) | 1996-12-31 | 1997-12-31 | グルタチオンの医薬製剤およびその投与方法 |
Country Status (8)
Country | Link |
---|---|
US (5) | US6159500A (ja) |
EP (1) | EP0957901B1 (ja) |
JP (1) | JP2001507696A (ja) |
AT (1) | ATE448782T1 (ja) |
AU (1) | AU5620598A (ja) |
CA (2) | CA2276183C (ja) |
DE (1) | DE69739663D1 (ja) |
WO (1) | WO1998029101A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005104852A (ja) * | 2003-09-29 | 2005-04-21 | Kyowa Hakko Kogyo Co Ltd | モービリウィルス感染症の予防または治療用組成物 |
WO2009099132A1 (ja) * | 2008-02-05 | 2009-08-13 | Kyowa Hakko Bio Co., Ltd. | グルタチオンの保存安定性向上方法 |
JP2010216917A (ja) * | 2009-03-16 | 2010-09-30 | Teikyo Univ | Ed評価方法 |
WO2013122188A1 (ja) * | 2012-02-15 | 2013-08-22 | 協和発酵バイオ株式会社 | 血管内皮機能低下の予防または改善剤 |
WO2014112641A1 (ja) * | 2013-01-21 | 2014-07-24 | 協和発酵バイオ株式会社 | 一酸化窒素濃度上昇剤 |
JP2017534673A (ja) * | 2014-09-15 | 2017-11-24 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 精神病性障害を治療するための方法および組成物 |
JP2018517781A (ja) * | 2015-06-19 | 2018-07-05 | モレキュラー ディフェンシズ コーポレイション | グルタチオン製剤およびその使用方法 |
WO2022168169A1 (ja) * | 2021-02-02 | 2022-08-11 | 学校法人日本医科大学 | 抗ウイルス剤 |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744593A (en) * | 1996-02-15 | 1998-04-28 | Heska Corporation | Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules |
US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
US6896899B2 (en) * | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
US20080275104A1 (en) * | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US20040072138A1 (en) * | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
AU745209B2 (en) * | 1998-01-06 | 2002-03-14 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
RU2144374C1 (ru) * | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
US20070142267A1 (en) * | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
GB2367489B (en) * | 2000-07-31 | 2005-02-09 | Mars Inc | Use of antioxidants |
EP1257273A2 (en) | 1999-08-17 | 2002-11-20 | University of Saskatchewan Technologies Inc. | Improved treatment for acute physical insult to the central nervous system |
US6642274B1 (en) | 1999-09-09 | 2003-11-04 | Gary W. Neal | Methods and compositions for preventing and treating prostate disorders |
AU7360700A (en) * | 1999-09-09 | 2001-04-10 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
EP1086695B1 (en) * | 1999-09-21 | 2004-12-22 | Enzo Leone | Antiviral compositions comprising yohimbine as active principle |
WO2001068069A2 (en) * | 2000-03-15 | 2001-09-20 | King's College London | Pharmaceutical composition comprising paracetamol |
CA2404157A1 (en) * | 2000-03-28 | 2001-10-04 | Robert J. Delorenzo | Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
WO2001076604A1 (en) * | 2000-04-07 | 2001-10-18 | Sang Geon Kim | Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz |
GB0008689D0 (en) * | 2000-04-07 | 2000-05-31 | Nokia Networks Oy | A method and system for processing signals |
US6762202B2 (en) * | 2000-05-09 | 2004-07-13 | Nitromed, Inc. | Infrared thermography and methods of use |
US6528520B2 (en) * | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
WO2002026223A2 (en) * | 2000-09-29 | 2002-04-04 | Board Of Trustees Operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
US7179791B2 (en) * | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
US20020169112A1 (en) * | 2001-05-08 | 2002-11-14 | Luc Montagnier | Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections |
US20030096770A1 (en) * | 2001-07-11 | 2003-05-22 | Krotz Achim H. | Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants |
CA2459556A1 (en) * | 2001-09-14 | 2003-03-27 | Roke Manor Research Limited | Low cost tagging system |
US6726809B2 (en) * | 2001-09-26 | 2004-04-27 | Albany International Corp. | Industrial process fabric |
ATE451105T1 (de) * | 2001-10-16 | 2009-12-15 | Univ Kansas | Neue prodrugs von n-h-bindung enthaltenden verbindungen und verfahren zu ihrer herstellung |
US20040241256A1 (en) * | 2002-12-05 | 2004-12-02 | Seymour Ehrenpreis | Medicinal compositions & therapeutic methods |
US7407986B2 (en) * | 2001-12-18 | 2008-08-05 | Brassica Foundation For Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes |
US20030194453A1 (en) * | 2002-04-15 | 2003-10-16 | Coleman Henry D. | Dietary supplement |
US20060099239A1 (en) * | 2002-04-15 | 2006-05-11 | Coleman Henry D | Dietary supplement for promoting removal of heavy metals from the body |
US20040213829A1 (en) * | 2002-04-15 | 2004-10-28 | Coleman Henry D. | Dietary supplement |
US20090011048A1 (en) * | 2002-04-16 | 2009-01-08 | Coleman Henry D | Dietary Supplement For Promoting Removal Of Heavy Metals From The Body |
WO2003092479A2 (en) * | 2002-05-03 | 2003-11-13 | Luc Montagnier | Treatments and methods for the treatment, diagnosis and prophylaxis |
US20070065497A1 (en) * | 2005-09-20 | 2007-03-22 | Guilford Frederick T | Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy |
US20100316700A1 (en) * | 2002-11-07 | 2010-12-16 | Guilford F Timothy | Systemic administration of liposomal reduced glutathione for the decorporation of radioactive materials and non-radioactive mercury |
WO2004055165A2 (en) * | 2002-12-13 | 2004-07-01 | St. Jude Children's Research Hospital | Glutathione-s-transferase test for susceptibility to parkinson's |
US20040229815A1 (en) * | 2003-01-03 | 2004-11-18 | Nagasawa Herbert T. | Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug |
DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
ATE377060T1 (de) * | 2003-02-21 | 2007-11-15 | Metabolix Inc | Pha-klebstoffe |
US7781539B2 (en) * | 2003-02-21 | 2010-08-24 | Metabolix Inc. | PHA blends |
US8076060B2 (en) * | 2003-08-04 | 2011-12-13 | Emil William Chynn | Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma |
US20070276024A1 (en) * | 2003-10-09 | 2007-11-29 | Inverseon , Inc. | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists |
US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
US20050143300A1 (en) * | 2003-10-10 | 2005-06-30 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
BRPI0415409A (pt) * | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
US20050130897A1 (en) * | 2003-12-11 | 2005-06-16 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
MXPA06007378A (es) * | 2003-12-23 | 2007-01-26 | Musc Found For Res Dev | Metodos y composiciones para la prevencion y tratamiento de enfermedades o condiciones inflamatorias. |
WO2005066256A1 (en) * | 2003-12-30 | 2005-07-21 | Metabolix, Inc. | Nucleating agents |
US20050202521A1 (en) * | 2004-03-10 | 2005-09-15 | Albert Crum | Methods of assessing the need for and the effectiveness of therapy with antioxidants |
WO2005115173A1 (en) * | 2004-05-24 | 2005-12-08 | Ott David M | Medicinal products incorporating bound organosulfur groups |
WO2006028991A2 (en) | 2004-09-03 | 2006-03-16 | Kyowa Hakko Kogyo Co., Ltd. | Composition and method for prevention or treatment of stomatits |
US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
WO2006060120A2 (en) * | 2004-11-07 | 2006-06-08 | Guilford F Timothy | Liposomal formulation for oral administration of glutathione (reduced) |
BRPI0519755A2 (pt) * | 2004-12-21 | 2009-03-10 | Critical Care Connections Inc | composiÇÕes ou combinaÇÕes nutrientes terapÊuticas e uso dos mesmos |
JP5069131B2 (ja) * | 2005-01-27 | 2012-11-07 | エリモス・ファーマスーティカルズ・エルエルシー | 動物へのndga化合物を包含するカテコールブタンの注射のための製剤 |
CN101150956B (zh) * | 2005-01-27 | 2013-04-17 | 埃里莫斯医药品有限公司 | 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方 |
WO2006091610A2 (en) * | 2005-02-23 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Inhibitors of enveloped virus infectivity |
JP5274248B2 (ja) | 2005-05-27 | 2013-08-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子 |
US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
CA2615319A1 (en) * | 2005-07-13 | 2007-01-18 | Al Czap | Compositions for oral administration of sustained release glutathione, methods for their production and uses thereof |
US20110112032A1 (en) * | 2005-09-12 | 2011-05-12 | Ming-He Huang | Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases |
GB2430364A (en) * | 2005-09-22 | 2007-03-28 | Carl Ernest Alexander | Soft agar bolus for oral drug delivery |
US8093207B2 (en) * | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
EA010926B1 (ru) * | 2006-01-20 | 2008-12-30 | Леонид Андреевич Кожемякин | Средство для лечения туберкулеза глаз, способ его получения и применения |
US20090047340A1 (en) * | 2006-03-29 | 2009-02-19 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis |
AU2007303050B2 (en) | 2006-10-05 | 2013-11-07 | Fred Hutchinson Cancer Research Center | Liquid chalcogenide compositions and methods of manufacturing and using the same |
WO2008112887A1 (en) * | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US20080287341A1 (en) * | 2007-05-18 | 2008-11-20 | Danyang Chen | Treatment of vascular abnormalities using nanoparticles |
EP2170356A1 (en) | 2007-06-25 | 2010-04-07 | Fred Hutchinson Cancer Research Center | Methods and compositions regarding polychalcogenide compositions |
GB0722923D0 (en) * | 2007-11-22 | 2008-01-02 | Uhi Millennium Inst | Improved anti-platelet compositions |
WO2009102050A1 (ja) * | 2008-02-15 | 2009-08-20 | Ajinomoto Co., Inc. | 腸管免疫賦活剤 |
WO2010044875A2 (en) * | 2008-10-16 | 2010-04-22 | Novan, Inc. | Nitric oxide releasing particles for oral care applications |
US8313456B2 (en) * | 2009-06-30 | 2012-11-20 | Palo Alto Research Center Incorporated | Drug-transfer device, drug-delivery system incorporating the same, methods of fabricating the same, and methods of enabling administration of a drug |
EP2467127B1 (en) | 2009-08-21 | 2023-08-02 | Novan, Inc. | Topical gels |
BR112012003804B1 (pt) | 2009-08-21 | 2019-02-19 | Novan, Inc. | Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento |
US20110064828A1 (en) * | 2009-09-11 | 2011-03-17 | Novelos Therapeutics, Incorporated | Treatment of metastatic tumors and other conditions |
EP2488591A1 (en) * | 2009-10-13 | 2012-08-22 | Novan, Inc. | Nitric oxide-releasing coatings |
WO2011091807A1 (en) * | 2010-01-31 | 2011-08-04 | Abdelrahman Shata Mohammed Shata | Anticoagulant and glutathione for treatment of cancer |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
US20130323324A1 (en) * | 2012-06-01 | 2013-12-05 | Franco Cavaleri | Vanadium and vanadyl amino acid complexes |
US20140179615A1 (en) * | 2012-07-12 | 2014-06-26 | Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. | Glutathione and Acetaminophen Composition and Preparation Method Thereof |
US9475930B2 (en) | 2012-08-17 | 2016-10-25 | Metabolix, Inc. | Biobased rubber modifiers for polymer blends |
ES2659199T3 (es) * | 2012-09-28 | 2018-03-14 | Kyowa Hakko Bio Co., Ltd. | Agente para aumentar la inmunidad que contiene glutatión |
US20140100283A1 (en) * | 2012-10-05 | 2014-04-10 | Atlantic Pro Nutrients, Inc. dba XYMOGEN | Method to Increase Absorption and Bioavailability of Oral Glutathione |
US10669417B2 (en) | 2013-05-30 | 2020-06-02 | Cj Cheiljedang Corporation | Recyclate blends |
EA201990684A1 (ru) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | Способы применения оксигенированных холестеролсульфатов (ocs) |
JP6573620B2 (ja) | 2014-02-10 | 2019-09-11 | フレッド ハッチンソン キャンサー リサーチ センター | 心臓発作及び虚血損傷のハロゲン治療 |
EP3185862A4 (en) * | 2014-10-09 | 2020-07-29 | Albert Crum | PROTECTIVE METALOTHION ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES |
WO2017091737A1 (en) * | 2015-11-25 | 2017-06-01 | Molecular Defenses Corporation | Pharmaceutical formulations |
US10702590B2 (en) * | 2016-04-12 | 2020-07-07 | Script Essentials, Llc | Compositions and methods for treating thyroid disease |
WO2018007878A1 (en) * | 2016-07-05 | 2018-01-11 | CanTrust LifeScience Corp. | Methods of treating and preventing gout and lead nephropathy |
US11602555B2 (en) | 2016-11-17 | 2023-03-14 | Renovion, Inc. | Treatment of respiratory tract diseases and infections with ascorbic acid compositions |
CA3082900A1 (en) | 2017-11-17 | 2019-05-23 | Renovion, Inc. | Stable ascorbic acid compositions and methods of using the same |
US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
EP3733197A1 (en) * | 2019-04-30 | 2020-11-04 | Stephen N. Pitcher | Anaerobic antioxidant composition |
WO2023199241A1 (en) * | 2022-04-12 | 2023-10-19 | URIACH ITALY S.r.l. | Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof |
WO2023199244A1 (en) * | 2022-04-12 | 2023-10-19 | URIACH ITALY S.r.l. | Composition comprising n-acetylcysteine, vitamin d and preferably glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof |
KR102602347B1 (ko) * | 2022-05-09 | 2023-11-15 | 천현수 | 위장내 발암성 엔-니트로사민 생성 억제 및 장내 산화질소 생성 촉진용 천연 조성물 및 이의 용도 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1444024A (en) * | 1973-07-20 | 1976-07-28 | Passwaterr A | Food and feed supplents |
FR2461002A1 (fr) | 1979-07-13 | 1981-01-30 | Inst Nat Sante Rech Med | Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede |
US4381307A (en) | 1980-10-31 | 1983-04-26 | Merck & Co., Inc. | Soft tertiary amine esters of bio-affecting carboxylic acids |
US4477435A (en) | 1981-05-19 | 1984-10-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for regenerating corneal epithelium |
US4414212A (en) * | 1981-12-10 | 1983-11-08 | Graham J. Naylor | Method of treatment of pre-menstrual syndrome |
US4454125A (en) | 1982-04-22 | 1984-06-12 | Demopoulos Harry B | Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof |
US4770877A (en) | 1982-08-03 | 1988-09-13 | Boston Biomedical Research Institute | Isolation of a high molecular weight aortic endothelial cell growth inhibitor |
US4534967A (en) | 1982-08-03 | 1985-08-13 | Boston Biomedical Research Institute | Cell proliferation inhibitor and method of preparation |
DE3686927T2 (de) | 1985-02-26 | 1993-03-25 | Univ Johns Hopkins | Neovaskularisierungsinhibitoren und deren herstellung. |
JPS62169723A (ja) * | 1986-01-22 | 1987-07-25 | Teisan Seiyaku Kk | 徐放化製剤 |
US6030950A (en) * | 1987-07-09 | 2000-02-29 | Ohlenschlaeger; Gerhard | Pharmaceutical therapeutic use of glutathione derivative |
US5061729A (en) | 1988-06-08 | 1991-10-29 | Biogal Gyogyszergyar | Pharmaceutical composition and process for preparing the same |
IT1231012B (it) | 1989-07-27 | 1991-11-08 | Zambon Spa | Composizione farmaceutica per uso orale contenente nac. |
JP2919870B2 (ja) * | 1989-09-29 | 1999-07-19 | 千寿製薬株式会社 | 肝障害抑制剤 |
US5238683A (en) | 1989-11-24 | 1993-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs |
ES2244529T3 (es) | 1991-02-01 | 2005-12-16 | Daiichi Suntory Pharma Co., Ltd. | Composiciones antibacterianas orales y metodo para la mejora de la absorcion gastrointestinal de los antibioticos de penemo o carbapenemo. |
US5747459A (en) * | 1991-02-04 | 1998-05-05 | Nestec, Ltd. | Method for insuring adequate intracellular glutathione in tissue |
US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
WO1993013660A1 (en) * | 1992-01-06 | 1993-07-22 | Health Maintenance Programs, Inc. | Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
US5204114A (en) | 1992-03-30 | 1993-04-20 | Health Maintenance Programs, Inc. | Methods of manufacturing high dosage glutathione the tablets and capsules produced thereby |
AU661379B2 (en) * | 1992-04-23 | 1995-07-20 | Transcend Therapeutics, Inc | Method of reducing or preventing toxicity associated with antiretroviral therapy |
US5840686A (en) | 1992-09-24 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use |
US6319687B1 (en) | 1992-09-24 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene |
US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
AU6060694A (en) * | 1993-05-10 | 1994-11-17 | Transcend Therapeutics, Inc | Method for treating acquired immune deficiency syndrome |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
AU4701593A (en) | 1993-07-22 | 1995-02-20 | Esseti S.A.S. Laboratorio Chimico Farmaco Biologico Di A. Ievoli & C. | Oral pharmaceutical compositions comprising reduced glutathion |
US5994339A (en) | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
US5985926A (en) | 1993-11-01 | 1999-11-16 | Cell Therapeutics, Inc. | Method for inhibiting intracellular viral replication |
US5679541A (en) | 1994-02-14 | 1997-10-21 | California Institute Of Technology | Programmed cell death antagonist protein |
US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
US6015665A (en) | 1995-02-13 | 2000-01-18 | The Regents Of The University Of Michigan | Method and composition for regulating apoptosis |
US5929063A (en) | 1995-03-24 | 1999-07-27 | Children's Hospital Medical Center | Mercapto and seleno derivatives as inhibitors of nitric oxide synthase |
US5674907A (en) | 1995-03-24 | 1997-10-07 | Children's Hospital Medical Center | Mercapto derivatives as inhibitors of nitric oxide synthase |
US5681711A (en) | 1995-03-27 | 1997-10-28 | University Of California-Los Angeles | Method for promoting apoptosis in mammalian neual cells |
US5804376A (en) | 1995-05-02 | 1998-09-08 | Incyte Pharmaceuticals, Inc. | Pancreas-derived serpin |
US5624955A (en) * | 1995-05-03 | 1997-04-29 | Regents Of The University Of Minnesota | Compounds that enhance the concentration of glutathione in tissues |
BR9608776A (pt) * | 1995-05-19 | 2000-10-24 | New York Blood Ct Inc | Processo de uso de ftalocianinas para inativar parasitas do sangue |
US5932425A (en) | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
US6011067A (en) | 1999-06-11 | 2000-01-04 | Thione International, Inc. | Antioxidant composition for the treatment of psoriasis and related diseases |
-
1997
- 1997-12-31 AU AU56205/98A patent/AU5620598A/en not_active Abandoned
- 1997-12-31 EP EP97952640A patent/EP0957901B1/en not_active Expired - Lifetime
- 1997-12-31 WO PCT/US1997/023879 patent/WO1998029101A1/en active Application Filing
- 1997-12-31 AT AT97952640T patent/ATE448782T1/de not_active IP Right Cessation
- 1997-12-31 JP JP53020698A patent/JP2001507696A/ja active Pending
- 1997-12-31 US US09/002,100 patent/US6159500A/en not_active Expired - Lifetime
- 1997-12-31 DE DE69739663T patent/DE69739663D1/de not_active Expired - Fee Related
- 1997-12-31 CA CA002276183A patent/CA2276183C/en not_active Expired - Fee Related
- 1997-12-31 US US09/331,947 patent/US6350467B1/en not_active Expired - Lifetime
- 1997-12-31 CA CA002650204A patent/CA2650204A1/en not_active Abandoned
-
1999
- 1999-12-09 US US09/457,642 patent/US6204248B1/en not_active Expired - Lifetime
-
2001
- 2001-03-19 US US09/813,247 patent/US6423687B1/en not_active Expired - Lifetime
-
2002
- 2002-07-22 US US10/200,852 patent/US6586404B1/en not_active Expired - Lifetime
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005104852A (ja) * | 2003-09-29 | 2005-04-21 | Kyowa Hakko Kogyo Co Ltd | モービリウィルス感染症の予防または治療用組成物 |
WO2009099132A1 (ja) * | 2008-02-05 | 2009-08-13 | Kyowa Hakko Bio Co., Ltd. | グルタチオンの保存安定性向上方法 |
JPWO2009099132A1 (ja) * | 2008-02-05 | 2011-05-26 | 協和発酵バイオ株式会社 | グルタチオンの保存安定性向上方法 |
JP5406049B2 (ja) * | 2008-02-05 | 2014-02-05 | 協和発酵バイオ株式会社 | グルタチオンの保存安定性向上方法 |
US9918951B2 (en) | 2008-02-05 | 2018-03-20 | Kyowa Hakko Bio Co., Ltd. | Method for improving storage stability of glutathione |
JP2010216917A (ja) * | 2009-03-16 | 2010-09-30 | Teikyo Univ | Ed評価方法 |
WO2013122188A1 (ja) * | 2012-02-15 | 2013-08-22 | 協和発酵バイオ株式会社 | 血管内皮機能低下の予防または改善剤 |
JPWO2013122188A1 (ja) * | 2012-02-15 | 2015-05-18 | 協和発酵バイオ株式会社 | 血管内皮機能低下の予防または改善剤 |
JPWO2014112641A1 (ja) * | 2013-01-21 | 2017-01-19 | 協和発酵バイオ株式会社 | 一酸化窒素濃度上昇剤 |
WO2014112641A1 (ja) * | 2013-01-21 | 2014-07-24 | 協和発酵バイオ株式会社 | 一酸化窒素濃度上昇剤 |
AU2014208077B2 (en) * | 2013-01-21 | 2018-05-24 | Kyowa Hakko Bio Co., Ltd. | Nitric oxide concentration elevating agent |
US11654125B2 (en) | 2013-01-21 | 2023-05-23 | Kyowa Hakko Bio Co., Ltd. | Agent for elevating nitric oxide concentration |
JP2017534673A (ja) * | 2014-09-15 | 2017-11-24 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 精神病性障害を治療するための方法および組成物 |
JP2021181473A (ja) * | 2014-09-15 | 2021-11-25 | サウンド・ファーマシューティカルズ・インコーポレイテッド | 精神病性障害を治療するための方法および組成物 |
JP2018517781A (ja) * | 2015-06-19 | 2018-07-05 | モレキュラー ディフェンシズ コーポレイション | グルタチオン製剤およびその使用方法 |
WO2022168169A1 (ja) * | 2021-02-02 | 2022-08-11 | 学校法人日本医科大学 | 抗ウイルス剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0957901A1 (en) | 1999-11-24 |
AU5620598A (en) | 1998-07-31 |
EP0957901B1 (en) | 2009-11-18 |
US6350467B1 (en) | 2002-02-26 |
CA2276183C (en) | 2009-06-09 |
DE69739663D1 (de) | 2009-12-31 |
CA2650204A1 (en) | 1998-07-09 |
US6586404B1 (en) | 2003-07-01 |
US6204248B1 (en) | 2001-03-20 |
US6423687B1 (en) | 2002-07-23 |
ATE448782T1 (de) | 2009-12-15 |
CA2276183A1 (en) | 1998-07-09 |
WO1998029101A1 (en) | 1998-07-09 |
US6159500A (en) | 2000-12-12 |
EP0957901A4 (en) | 2006-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001507696A (ja) | グルタチオンの医薬製剤およびその投与方法 | |
US6896899B2 (en) | Pharmaceutical preparations of glutathione and methods of administration thereof | |
US5292773A (en) | Treating aids and HIV infection with methionine | |
CN108135964B (zh) | 谷胱甘肽制剂和使用方法 | |
CA2386990C (en) | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase | |
RU2711913C2 (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
AU2007203159B2 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
WO2011145343A1 (ja) | 5-アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬 | |
US20210228509A1 (en) | Prodrug for the treatment of disease and injury of oxidative stress | |
JP2006510714A (ja) | 放射線被爆患者の処置方法 | |
JP4580479B2 (ja) | 抗hiv感染症剤 | |
US6034126A (en) | Method for treating glycol poisoning | |
RU2096034C1 (ru) | Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием | |
US5998479A (en) | Method of treating adult respiratory syndrome | |
JPH04502020A (ja) | 腸内鉄吸収性を制御するための経口投与ポルフィリン類 | |
WO2000038682A1 (fr) | Agents de lutte contre les infections a vih et procede de traitement d'une infection a vih | |
CA2605707A1 (en) | Pharmaceutical preparations of glutathione and methods of administration thereof | |
US6291441B1 (en) | Method of treating inflammatory bowel disorders | |
US20120295977A1 (en) | Organosulfur prodrugs for the prevention and treatment of infectious diseases | |
JP2010184936A (ja) | 放射線被爆患者の処置方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041227 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050411 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080922 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090714 |